NFKB1 and acute myeloid leukemia: Interestingly, NF-κB signalling is constitutively active in AML LSCs but not in normal haematopoietic progenitor cells, indicating that the NF-κB pathway might be used as a selective target for anti-AML LSCs to kill this subset population [6, 9, 10].